How In-Cab Drowsiness Detection Systems Are Changing Sleep Apnea Screening for European Professional Drivers
Why driver drowsiness detection sleep apnea screening now begins in the cab rather than the clinic
Your new truck now flags the moment you fade at the wheel, and this guide decodes what that warning records, what it legally cannot do with your data, and where it lands you in the European Group 2 medical chain.
What Driver Drowsiness Detection Sleep Apnea Screening Means Inside a New EU Cab
Driver drowsiness detection sleep apnea screening is the indirect process by which a warning fitted to your vehicle flags repeated sleepiness, and that pattern becomes the reason a doctor finally investigates how you breathe at night. The vehicle diagnoses nothing, but a repeated signal is hard to argue with at your next fitness to drive medical.
Since 7 July 2024, every new car, van, truck and bus registered in the European Union must carry a driver drowsiness and attention warning (DDAW) system under Regulation (EU) 2019/2144, the General Safety Regulation known as GSR2. New vehicle types have had one since 6 July 2022. The rules that govern your licence sit in the EU framework for HGV drivers under Directive 2014/85/EU, not in a foreign medical-card scheme.
From 7 July 2026, every newly registered EU vehicle also carries camera-based attention monitoring. A 2023 editorial in the journal SLEEP (Oxford Academic) noted that preliminary studies suggest drowsiness monitoring technology can distinguish which sleep apnea patients have regular episodes of drowsiness while driving. The safety case is covered in our guide to the risks of drowsy driving.
- DDAW is mandatory on all newly registered EU vehicles since 7 July 2024 under Regulation (EU) 2019/2144.
- It is a safety warning, not a diagnostic test, but a repeated pattern is clinically meaningful.
- The alert is the start of a medical pathway, not the end of one.
DDAW and ADDW Are Two Different Systems and Drivers Confuse Them Constantly
DDAW assesses alertness. Advanced driver distraction warning (ADDW) assesses attention. They are separate legal obligations with separate deadlines, and confusing them makes drivers trust the wrong thing.
Most drivers assume a camera is watching their eyelids. Often it is not. Under Commission Delegated Regulation (EU) 2021/1341, many DDAW implementations infer drowsiness indirectly through vehicle systems analysis, reading steering wheel variability and lane departure detection rather than the face. DDAW applies above a maximum design speed of 70 km/h, so the benefit sits outside urban areas.
ADDW is the camera-based half. It uses head pose and infrared gaze tracking against mapped gaze zones, and became mandatory for new vehicle types on 7 July 2024 and for all newly registered EU vehicles on 7 July 2026. Critically, it does not address drowsiness or sleep disorders at all: it watches where you look, not how tired you are.
| System | What it monitors | What triggers it | All new EU registrations |
|---|---|---|---|
| DDAW | Alertness, largely via vehicle behaviour such as steering and lane keeping | Drowsiness at or above 8 on the Karolinska Sleepiness Scale, above 70 km/h design speed | 7 July 2024 |
| ADDW | Attention, via head position, eye movement and gaze direction | Gaze away from the road area; it does not assess sleep disorders | 7 July 2026 |
| Event data recorder | Crash-related vehicle data, a separate stream | A collision or comparable event, never sleepiness | 7 January 2026 for newly type-approved trucks and buses; 7 January 2029 for all new vehicles in those categories |
- DDAW watches the vehicle; ADDW watches your gaze.
- Your DDAW may never have looked at your eyes once.
- The event data recorder (EDR) is a third, unrelated data stream tied to crashes.
A Silent System Is Not a Clean Bill of Health
A DDAW that has never warned you does not mean you sleep well. The homologation bar is publicly documented and low. Under the DDAW technical requirements, a system is accepted if the average sensitivity is above 40%, or if the lower bound from the 90% confidence interval of the sensitivity results is above 20%.
Read that twice. A fully legal, type-approved system can miss a large share of genuine drowsiness episodes and still pass. So "my truck never beeps at me" is not evidence against obstructive sleep apnoea syndrome. It is evidence that the sampling is coarse.
Research settings measure the same thing far more directly. A 2024 study in the journal Sensors (PMC) tested 50 professional male drivers diagnosed with OSA at an apnoea-hypopnoea index of 5 or above. Using PERCLOS at or above 0.3 or eye closure of at least 2 seconds, 878 of 927 visually scored episodes matched EEG patterns, a 94.7% alignment, with the theta-alpha ratio strongest at r = 0.9942. The same 2023 SLEEP editorial reported that driver monitoring systems (DMS) with in-cabin alerts reduced drowsiness events by over 60% in occupational settings.
- EU type approval accepts a DDAW with average sensitivity just above 40%.
- No warnings does not equal no sleep-disordered breathing.
- Laboratory work measures drowsiness directly through PERCLOS percentage eyelid closure and EEG.
What a KSS 8 Warning Says About How Sleepy You Actually Were
The regulation requires a warning at a level of drowsiness equivalent to or above 8 on the Karolinska Sleepiness Scale. Level 8 means sleepy, with some effort needed to keep awake. It is the bridge from a beep to a symptom: the point where staying alert stops being automatic, and where a microsleep at the wheel, a lapse of a few seconds during which the vehicle is effectively unpiloted, becomes a real concern.
If that describes your mid-afternoon on a long haul, the next questions are nocturnal. Does your partner report loud snoring or witnessed apnoeas? Do you wake with a morning headache? Are you getting up at night to urinate, a symptom called nocturia? Those clues, combined with an objective alert, build a far stronger case than either signal alone.
- KSS 8 means sleepy, with real effort required to stay awake.
- Pair the alert with night-time symptoms before you dismiss it.
Who Can Actually See Your Drowsiness Alerts
The mandated systems are not a surveillance feed and not a medical file. Privacy here is legislated rather than left to vendor policy. ADDW must function without biometric information, including facial recognition, and operates closed-loop, retaining on the device only the data necessary for the system to function. Personal data processing within DDAW must comply with Union data protection law.
Three consequences follow. The alerts are not a medical record. They are not, by default, visible on a fleet manager's dashboard. And they cannot on their own trigger a referral, because no clinician receives them.
Crash data travels separately. Event data recorders became mandatory on newly type-approved trucks and buses on 7 January 2026, extending to all new vehicles in those categories on 7 January 2029, a distinct obligation that is not part of the drowsiness system. Any extra camera or telematics your employer installs is a commercial arrangement under your contract and national data protection law, not GSR2.
- ADDW is legally required to work without biometric identification.
- Closed-loop retention means the alert generally stays in the vehicle.
- Separate the drowsiness warning, the distraction warning and the EDR when discussing data with your employer.
How Driver Drowsiness Detection Sleep Apnea Referrals Work Step by Step in Europe
Because the vehicle cannot refer you, you refer yourself. The European pathway looks nothing like the one most search results describe.
1Start with the occupational physician or your GP
Book with médecine du travail, the Betriebsarzt, or your treating doctor. Bring the dates of your warnings, and frame it as fatigue at work rather than a licence problem.
2Complete the screening questionnaires
Expect the STOP-BANG questionnaire, the Epworth Sleepiness Scale and sometimes the Berlin Questionnaire. Your BMI and neck circumference are recorded here as established risk factors.
3Record a night at home
Home respiratory polygraphy, or polygraphie ventilatoire nocturne, measures airflow, effort and oxygen saturation in your own bed. Full polysomnography (PSG) is reserved for complex cases.
4Add a wakefulness test for Group 2
The Maintenance of Wakefulness Test (MWT), the test de maintien de l'éveil or TME in France, measures your ability to stay awake in soporific conditions. In France it is the reference examination for Groupe 2 and must be normal before resuming.
5Present to the approved examiner
In France the decision rests with a médecin agréé par la préfecture, not your treating physician. Other member states use their own designated assessors under Annex III.
- The chain runs occupational physician, questionnaires, home polygraphy, then MWT for Group 2.
- Non-EU compliance rules do not apply to a European licence.
- Going voluntarily is far better than being sent.
The Low Epworth Trap That Catches Professional Drivers
Professional drivers often under-report sleepiness on the very questionnaire their medical relies on. One European cohort shows the gap clearly.
A 2024 prospective cohort published via PMC studied 86 male Portuguese heavy-truck drivers with no prior diagnosis. It found that 77.9%, or 67 drivers, had obstructive sleep apnoea, with a mean AHI of 16.72 plus or minus 14.69 events per hour. Across the cohort, 34.88% were classified mild, 26.74% moderate and 16.28% severe. Yet only 8 drivers scored high on the Epworth Sleepiness Scale, mean ESS 4.30 plus or minus 3.2, while 14 reported previous episodes of falling asleep while driving.
More drivers had fallen asleep at the wheel than flagged themselves as sleepy on paper. That gap is why an objective in-cab signal matters, and an irregular schedule compounds it. Our guide to how night shifts mask the usual warning signs covers the same blind spot.
- A reassuring Epworth score does not rule out OSA in a professional driver.
- In that 2024 cohort, 14 drivers had dozed at the wheel while only 8 scored high on the ESS.
- Objective data counterweights self-reported sleepiness.
What Your AHI Result Means for a Group 2 Licence
Your apnoea-hypopnoea index, or IAH in French, decides the licensing conversation. Annex III of Directive 2006/126/EC, as amended by Commission Directive 2014/85/EU, defines moderate obstructive sleep apnoea syndrome as AHI 15 to 29 and severe as AHI 30 or above, in both cases combined with excessive daytime sleepiness (EDS).
| AHI band | Classification | Group 1 (car, motorcycle) | Group 2 (categories C, C1, CE, D, D1) |
|---|---|---|---|
| 5 to 14 | Mild, outside the Annex III bands | Usually no restriction | Usually no restriction; treat the symptoms, not the licence |
| 15 to 29 with EDS | Moderate OSAS | Possible with adequate control and treatment compliance; review at most every three years | Possible with documented control; review at most every year |
| 30 or above with EDS | Severe OSAS | Driving only where control of symptoms and treatment compliance are shown | In France, severe untreated SAOS at IAH 30 or more with significant daytime sleepiness is incompatible with driving, especially Groupe 2 |
France sets the detail in the arrêté du 28 mars 2022. PPC, or pression positive continue, the French term for CPAP, is judged at an average of at least 4 hours per night, with roughly four weeks of effective treatment before Groupe 2 resumption and a normal TME. Aptitude runs three years maximum for Groupe 1 and one year renewable for Groupe 2. Member states may impose stricter requirements.
Treatment changes the risk picture. The European Respiratory Review reported in 2015 that OSAS is associated with a 2 to 7-fold higher motor vehicle accident risk across studies, a meta-analysis figure of 2.4 times the general-population risk, and that sleepiness contributes to 5 to 7% of all motor vehicle accidents and roughly 17% of fatal ones. In the Ontario cohort described there, drivers had a 3-fold higher accident rate before diagnosis, with no significant difference from the general population after CPAP.
- Annex III thresholds are AHI 15 to 29 moderate and 30 or above severe, both with EDS.
- Group 2 review runs at intervals not exceeding one year; Group 1 at up to three years.
- Documented, treated drivers keep their entitlement under the same Annex III rules.
When the Diagnosis Comes Back Mild
Most drivers who follow an alert into the pathway are not told they have severe disease. In that 2024 Portuguese cohort, mild disease was the largest group at 34.88%, against 16.28% severe. Mild obstructive sleep apnoea at AHI 5 to 14, and heavy snoring without apnoeas, sit below the Annex III bands.
That usually means no licence restriction and no PPC prescription. It also means you go home still sleeping badly in a cab bunk. Practical levers here include weight and neck circumference, sleeping position, alcohol timing before bed, treating nasal obstruction, and a dentist-fitted mandibular advancement device, in France an orthèse d'avancée mandibulaire.
A nasal stent is another option in that mild band. Back2Sleep is a CE-certified Class I soft silicone intranasal stent that keeps the nasal airway open during sleep, sold without prescription, with a starter kit containing four sizes. It needs no electricity, makes no noise and uses no tubing, the practical point for a driver sleeping away from home.
- Mild results are a common outcome and the most neglected one.
- Non-CPAP options exist for snoring and mild-to-moderate cases.
- Nothing in this band substitutes for the licensing pathway when your AHI is 15 or above.
What Fleets Should Do With the Signal
Fatigue risk management for fleets works when the alert leads to a health conversation rather than a disciplinary one. Drivers who fear losing shifts are unlikely to report warnings, and the signal disappears.
Three measures are low cost and defensible. Offer voluntary, confidential screening using STOP-BANG through occupational health. Build medical appointments into rostered time rather than rest days. And write into policy that a driver who self-reports repeated drowsiness warnings faces no penalty. The American Academy of Sleep Medicine's public safety guidance, accessed in 2026, estimates OSA prevalence in commercial drivers at 28% to 60%, and the 2023 SLEEP editorial noted that most drowsiness events occur in a small proportion of drivers.
- Punitive use of drowsiness data destroys the data.
- Confidential screening and paid appointment time produce disclosure.
- At 28% to 60% prevalence, screening is a fleet-wide issue.
What Back2Sleep Users Say
Frequently Asked Questions
Can a truck drowsiness warning system detect sleep apnea?
No. A driver drowsiness and attention warning system detects sleepiness, not a breathing disorder. It cannot measure your apnoea-hypopnoea index or diagnose anything. What it can do is create an objective, repeated record of alertness failures, and a pattern of warnings is a legitimate reason to ask your occupational physician for sleep apnoea screening.
What does the driver drowsiness warning in my truck actually record?
Under Commission Delegated Regulation (EU) 2021/1341, many DDAW systems infer drowsiness indirectly from driving behaviour such as steering wheel variability and lane keeping, above 70 km/h. Any personal data processing must follow Union data protection law, and the newer distraction system must work without biometric information, including facial recognition, retaining only what it needs on the device.
Can my employer or fleet manager see my drowsiness alerts?
Not from the mandated system by itself. The EU distraction warning operates closed-loop and retains on the device only what it needs to function, so the alerts are not a medical record and not a management dashboard. Separate commercial telematics or camera equipment your employer installs is a different matter, governed by your contract and national data protection rules.
Do I have to declare sleep apnoea to keep my Group 2 licence in Europe?
Yes, in practice. Annex III of Directive 2006/126/EC, amended by Directive 2014/85/EU, requires drivers with moderate or severe obstructive sleep apnoea syndrome and excessive daytime sleepiness to be assessed. Licences can be issued where treatment is followed and controlled, with review at intervals not exceeding one year for Group 2. Member states may impose stricter rules.
How many drowsiness warnings is too many before I should see a doctor?
There is no regulatory or clinical threshold, so judge the pattern rather than the count. Warnings on separate days, an alert early in a shift, or an episode you cannot clearly recall all justify booking a consultation. Because a type-approved system may legally miss many genuine drowsiness episodes, treat each warning as a sample rather than a full count.
Is a home sleep apnoea test enough for a professional driver medical?
Often yes for the diagnosis itself. Home respiratory polygraphy, called polygraphie ventilatoire nocturne in France, records airflow, effort and oxygen levels in your own bed and can establish your apnoea-hypopnoea index. Full polysomnography is reserved for complex cases. In France, though, the Test de Maintien d'Éveil is the reference examination for Groupe 2.
Why does my drowsiness warning go off when I feel fine?
Because the regulation sets the trigger at drowsiness equivalent to or above 8 on the Karolinska Sleepiness Scale, meaning sleepy with some effort needed to stay awake. Professional drivers often under-report that state. In the 2024 Portuguese heavy-truck cohort, only 8 drivers scored high on the Epworth Sleepiness Scale while 14 reported already falling asleep at the wheel.
Is the in-cab drowsiness detection system a medical device?
No. It is type-approved vehicle safety equipment under Regulation (EU) 2019/2144, not a medical device, and it produces no diagnosis. Fitness to drive is decided through the Annex III medical assessment chain, which in France ends with a médecin agréé appointed by the préfecture rather than your own treating physician.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.